Nucleoside and non-nucleoside DOT1L inhibitors: dawn of MLLrearranged leukemia
M Cao, T Li, Y Chen, X Zhai - Mini Reviews in Medicinal …, 2021 - ingentaconnect.com
Herein, the underlying role of disruptor of telomeric silencing 1-like (DOT1L) as a therapeutic
target for mixed-lineage leukemia (MLL)-rearranged is comprehensively clarified. DOT1L …
target for mixed-lineage leukemia (MLL)-rearranged is comprehensively clarified. DOT1L …